FDA Approves Lucentis Biosimilar Nufymco - Poll - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

By
Conexiant News Staff
January 2, 2026
1 min

Ophthalmology Management

Share

Original Source(s)

Ophthalmology Management

FDA Approves Lucentis Biosimilar Nufymco

by Conexiant News Staff
January 2, 2026

Related Content

Frontiers In Medicine

Investigation of Ultrawidefield OCTA to Assess the Effects of Posterior Precorical Vitreous Pocket on Retinal and Choroidal Structure and Blood Flow

by Xida Liang, Jing Zeng, Ruiming Yang, Wanni Chen, Zhimeng Zhang, Junming Wang
April 24, 2026

Retinal Physician

New Strategies for Managing Diabetic Retinopathy

by Omar Saeed, MPH, Veeral S. Sheth, MD, MBA, FACS
May 1, 2026
12 min

Frontiers In Medicine

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease